Rhiana S Menen1, Nivetha Ganesan1, Therese Bevers2, Jun Ying3, Robin Coyne2, Deanna Lane4, Constance Albarracin5, Isabelle Bedrosian6. 1. Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2. Department of Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Biostatics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 6. Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ibedrosian@mdanderson.org.
Abstract
PURPOSE: Atypical ductal hyperplasia (ADH) found on core biopsy is associated with an upgrade to carcinoma in 10-30 % of women, thus surgical excision remains the standard of care. This study compares the incidence of breast cancer in women with ADH who were observed with those who underwent surgical excision of the ADH site. METHODS: Our departmental, prospectively maintained registry was reviewed to identify patients with ADH diagnosed by core biopsy. Surgically treated patients were excluded if upstaged to carcinoma following excision for ADH diagnosis. Breast cancer events were classified as index site (site of ADH biopsy), ipsilateral breast unrelated to index site, or contralateral breast. RESULTS: Overall, 175 women met the study criteria; 125 were observed and 50 underwent excision. With a median follow-up of 3 years, 14 breast cancer events were noted in 13 patients. In the surgery group, six women developed breast cancer (12 %), including one bilateral, compared with seven cancers (5.6 %) in the observed group (p = 0.14). Index site events and ipsilateral cancers were the same in both groups [2 vs. 0.8 % (p = 0.49) and 4 versus 4.8 % (p = 1.00), respectively]. All contralateral cancers occurred in the surgical group (8 vs. 0 %; p < 0.01). A prior history of breast cancer was the only variable associated with subsequent breast cancer events (hazard ratio 12.53, 95 % confidence interval 3.30-47.57). CONCLUSION: Observation is appropriate in selected women with ADH on core biopsy. Index site failures are rare and are superseded by cancer risk elsewhere in the breast.
PURPOSE:Atypical ductal hyperplasia (ADH) found on core biopsy is associated with an upgrade to carcinoma in 10-30 % of women, thus surgical excision remains the standard of care. This study compares the incidence of breast cancer in women with ADH who were observed with those who underwent surgical excision of the ADH site. METHODS: Our departmental, prospectively maintained registry was reviewed to identify patients with ADH diagnosed by core biopsy. Surgically treated patients were excluded if upstaged to carcinoma following excision for ADH diagnosis. Breast cancer events were classified as index site (site of ADH biopsy), ipsilateral breast unrelated to index site, or contralateral breast. RESULTS: Overall, 175 women met the study criteria; 125 were observed and 50 underwent excision. With a median follow-up of 3 years, 14 breast cancer events were noted in 13 patients. In the surgery group, six women developed breast cancer (12 %), including one bilateral, compared with seven cancers (5.6 %) in the observed group (p = 0.14). Index site events and ipsilateral cancers were the same in both groups [2 vs. 0.8 % (p = 0.49) and 4 versus 4.8 % (p = 1.00), respectively]. All contralateral cancers occurred in the surgical group (8 vs. 0 %; p < 0.01). A prior history of breast cancer was the only variable associated with subsequent breast cancer events (hazard ratio 12.53, 95 % confidence interval 3.30-47.57). CONCLUSION: Observation is appropriate in selected women with ADH on core biopsy. Index site failures are rare and are superseded by cancer risk elsewhere in the breast.
Authors: Xiao-Jun Ma; Ranelle Salunga; J Todd Tuggle; Justin Gaudet; Edward Enright; Philip McQuary; Terry Payette; Maria Pistone; Kimberly Stecker; Brian M Zhang; Yi-Xiong Zhou; Heike Varnholt; Barbara Smith; Michelle Gadd; Erica Chatfield; Jessica Kessler; Thomas M Baer; Mark G Erlander; Dennis C Sgroi Journal: Proc Natl Acad Sci U S A Date: 2003-04-24 Impact factor: 11.205
Authors: Paul E Goss; James N Ingle; José E Alés-Martínez; Angela M Cheung; Rowan T Chlebowski; Jean Wactawski-Wende; Anne McTiernan; John Robbins; Karen C Johnson; Lisa W Martin; Eric Winquist; Gloria E Sarto; Judy E Garber; Carol J Fabian; Pascal Pujol; Elizabeth Maunsell; Patricia Farmer; Karen A Gelmon; Dongsheng Tu; Harriet Richardson Journal: N Engl J Med Date: 2011-06-04 Impact factor: 91.245
Authors: Christopher V Nguyen; Constance T Albarracin; Gary J Whitman; Adriana Lopez; Nour Sneige Journal: Ann Surg Oncol Date: 2010-10-23 Impact factor: 5.344
Authors: Jack Cuzick; Andrea DeCensi; Banu Arun; Powel H Brown; Monica Castiglione; Barbara Dunn; John F Forbes; Agnes Glaus; Anthony Howell; Gunter von Minckwitz; Victor Vogel; Heinz Zwierzina Journal: Lancet Oncol Date: 2011-05 Impact factor: 41.316
Authors: Joann G Elmore; Gary M Longton; Patricia A Carney; Berta M Geller; Tracy Onega; Anna N A Tosteson; Heidi D Nelson; Margaret S Pepe; Kimberly H Allison; Stuart J Schnitt; Frances P O'Malley; Donald L Weaver Journal: JAMA Date: 2015-03-17 Impact factor: 56.272
Authors: Bernard Fisher; Joseph P Costantino; D Lawrence Wickerham; Reena S Cecchini; Walter M Cronin; Andre Robidoux; Therese B Bevers; Maureen T Kavanah; James N Atkins; Richard G Margolese; Carolyn D Runowicz; Joan M James; Leslie G Ford; Norman Wolmark Journal: J Natl Cancer Inst Date: 2005-11-16 Impact factor: 13.506
Authors: Laura C Collins; Heather J Baer; Rulla M Tamimi; James L Connolly; Graham A Colditz; Stuart J Schnitt Journal: Cancer Date: 2007-01-15 Impact factor: 6.860
Authors: Amy C Degnim; Daniel W Visscher; Hal K Berman; Marlene H Frost; Thomas A Sellers; Robert A Vierkant; Shaun D Maloney; V Shane Pankratz; Piet C de Groen; Wilma L Lingle; Karthik Ghosh; Lois Penheiter; Thea Tlsty; L Joseph Melton; Carol A Reynolds; Lynn C Hartmann Journal: J Clin Oncol Date: 2007-06-11 Impact factor: 44.544
Authors: Suzanne B Coopey; Emanuele Mazzola; Julliette M Buckley; John Sharko; Ahmet K Belli; Elizabeth M H Kim; Fernanda Polubriaginof; Giovanni Parmigiani; Judy E Garber; Barbara L Smith; Michele A Gadd; Michelle C Specht; Anthony J Guidi; Constance A Roche; Kevin S Hughes Journal: Breast Cancer Res Treat Date: 2012-11-02 Impact factor: 4.872
Authors: Simukayi Mutasa; Peter Chang; John Nemer; Eduardo Pascual Van Sant; Mary Sun; Alison McIlvride; Maham Siddique; Richard Ha Journal: Clin Breast Cancer Date: 2020-06-07 Impact factor: 3.225
Authors: Christoph J Rageth; Elizabeth A M O'Flynn; Katja Pinker; Rahel A Kubik-Huch; Alexander Mundinger; Thomas Decker; Christoph Tausch; Florian Dammann; Pascal A Baltzer; Eva Maria Fallenberg; Maria P Foschini; Sophie Dellas; Michael Knauer; Caroline Malhaire; Martin Sonnenschein; Andreas Boos; Elisabeth Morris; Zsuzsanna Varga Journal: Breast Cancer Res Treat Date: 2018-11-30 Impact factor: 4.872